Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.49 |
| ▸ | SOAT1 | P35610 | 5/20 | 0.48 |
| ▸ | SOAT2 | O75908 | 3/20 | 0.48 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CETP | P11597 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30516912 | 0.94 | POLB (0.51) | POLBLMNAHSP90AA1HSP90AB1RAB9A | |
| SCHEMBL1863751 | 0.90 | POLB (0.46) | POLBLMNAHSP90AA1HSP90AB1SOAT1 | |
| SCHEMBL1867068 | 0.90 | POLB (0.46) | POLBLMNAHSP90AA1HSP90AB1SOAT1 | |
| SCHEMBL4138545 | 0.89 | KMT2A (0.48) | POLBLMNAHSP90AA1HSP90AB1SOAT1 | |
| SCHEMBL1863466 | 0.87 | POLB (0.48) | POLBLMNAHSP90AA1HSP90AB1SOAT1 | |
| SCHEMBL5849567 | 0.84 | POLB (0.56) | POLBHSP90AA1HSP90AB1KMT2AMAPK1 | |
| SCHEMBL4124902 | 0.82 | POLB (0.44) | POLBHSP90AA1HSP90AB1HPGDKMT2A | |
| SCHEMBL26789473 | 0.81 | POLB (0.59) | POLBHSP90AA1HSP90AB1RAB9AHPGD | |
| SCHEMBL4133128 | 0.80 | PKM (0.56) | KMT2A | |
| SCHEMBL13678948 | 0.79 | CTSK (0.42) | POLBHSP90AA1HSP90AB1KMT2ACTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105597-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2011-05-05 | — | — | US | disclosed |
| US-20110105597-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2011-05-05 | — | — | US | disclosed |
| US-20110105597-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2011-05-05 | — | — | US | disclosed |
| US-20100280036-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2010-11-04 | — | — | US | disclosed |
| US-20100280036-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2010-11-04 | — | — | US | disclosed |
| US-20090076012-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2009-03-19 | — | — | US | disclosed |
| US-20090076012-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2009-03-19 | — | — | US | disclosed |
| US-20080214635-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-09-04 | — | — | US | disclosed |
| US-20080214635-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-09-04 | — | — | US | disclosed |
| US-20080194607-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-08-14 | — | — | US | disclosed |
| US-20080188536-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-08-07 | — | — | US | disclosed |
| US-20080188536-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-08-07 | — | — | US | disclosed |
| US-20080188491-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-08-07 | — | — | US | disclosed |
| US-20080182878-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-31 | — | — | US | disclosed |
| US-20080182878-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-31 | — | — | US | disclosed |
| US-20080182878-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-31 | — | — | US | disclosed |
| US-20080176938-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-24 | — | — | US | disclosed |
| US-20080176938-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-24 | — | — | US | disclosed |
| US-7335779-B2 | Modulation of pathogenicity | QUONOVA, LLC (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335779-B2 | Modulation of pathogenicity | QUONOVA, LLC (US) | 2008-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076012-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | POLB 3354/4885LMNA 3658/4885HSP90AA1 2484/4885 |
| US-20110105597-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | POLB 3327/4885LMNA 3684/4885HSP90AA1 2488/4885 |
| US-20080214635-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | POLB 3327/4885LMNA 3684/4885HSP90AA1 2488/4885 |
| US-20100280036-A1 | Modulation of Pathogenicity | NR4A1, NR4A2, NR4A3 | POLB 3327/4885LMNA 3684/4885HSP90AA1 2488/4885 |
| US-20080182878-A1 | Modulation of pathogenicity | NR4A1, NR4A2, MSR1 | POLB 3349/4885LMNA 3656/4885HSP90AA1 2491/4885 |
| US-20080188491-A1 | Modulation of pathogenicity | NR4A1, MSR1, NR4A2 | POLB 3265/4885LMNA 3578/4885HSP90AA1 2585/4885 |
| US-20080194607-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | POLB 3327/4885LMNA 3684/4885HSP90AA1 2488/4885 |
| US-20080188536-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | POLB 3327/4885LMNA 3684/4885HSP90AA1 2488/4885 |
| US-20080176938-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | POLB 3431/4885LMNA 3839/4885HSP90AA1 2253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.